| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
40,010,000 |
| Market
Cap: |
105.23(M) |
| Last
Volume: |
1,008,943 |
Avg
Vol: |
1,001,362 |
| 52
Week Range: |
$1.19 - $32.18 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : 11.2 |
| Insider 6 Months : 11.2 |
| Insider 3/6 Months : 22.6 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Cassava Sciences is a clinical-stage biotechnology company. Co. has combined technology with insights in neurobiology to develop solutions for Alzheimer's disease and other neurodegenerative diseases. Co. has two biopharmaceutical assets under development: its primary therapeutic product candidate, called simufilam, is a treatment for Alzheimer's disease; and its primary investigational diagnostic product candidate, called SavaDx, is a way to detect the existence of Alzheimer's disease from a small sample of blood.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
258,838 |
258,838 |
258,838 |
258,838 |
| Total Buy Value |
$591,035 |
$591,035 |
$591,035 |
$591,035 |
| Total People Bought |
2 |
2 |
2 |
2 |
| Total Buy Transactions |
4 |
4 |
4 |
4 |
| Total Shares Sold |
0 |
0 |
65,800 |
65,800 |
| Total Sell Value |
$0 |
$0 |
$253,948 |
$253,948 |
| Total People Sold |
0 |
0 |
2 |
2 |
| Total Sell Transactions |
0 |
0 |
3 |
3 |
| End Date |
2025-08-21 |
2025-05-20 |
2024-11-19 |
2023-11-20 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Barry Richard |
President & CEO |
• • – |
2025-11-19 |
4 |
B |
$2.75 |
$201,809 |
I/I |
73,385 |
788,060 |
2.66 |
- |
|
| Cook Robert Christopher |
Chief Operating & Legal Office |
• • – |
2025-09-30 |
4 |
B |
$2.91 |
$39,940 |
D/D |
13,725 |
13,725 |
2.74 |
-6% |
|
| Barry Richard |
President & CEO |
• • – |
2025-09-22 |
4 |
B |
$2.28 |
$16,352 |
I/I |
7,172 |
714,675 |
2.58 |
19% |
|
| Barry Richard |
President & CEO |
• • – |
2025-09-19 |
4 |
B |
$2.25 |
$108,319 |
I/I |
47,308 |
707,503 |
2.66 |
21% |
|
| Barry Richard |
President & CEO |
• • – |
2025-09-18 |
4 |
B |
$2.13 |
$426,424 |
I/I |
190,633 |
660,195 |
2.66 |
20% |
|
| Kupiec James William |
Chief Medical Officer |
• • – |
2024-11-29 |
4 |
S |
$3.87 |
$15,480 |
D/D |
(4,000) |
0 |
|
67% |
|
| Schoen Eric |
Chief Financial Officer |
• • – |
2024-11-29 |
4 |
S |
$3.86 |
$230,828 |
D/D |
(59,800) |
11,500 |
|
67% |
|
| Schoen Eric |
Chief Financial Officer |
• • – |
2024-11-29 |
4 |
S |
$3.82 |
$7,640 |
I/I |
(2,000) |
0 |
|
67% |
|
| Schoen Eric |
Chief Financial Officer |
• • – |
2024-11-29 |
4 |
OE |
$1.18 |
$59,000 |
D/D |
50,000 |
71,300 |
|
- |
|
| Robertson Sanford |
Director |
• • – |
2024-05-16 |
4 |
GA |
$0.00 |
$0 |
I/I |
5,000 |
5,000 |
|
- |
|
| Robertson Sanford |
Director |
• • – |
2024-05-16 |
4 |
GD |
$0.00 |
$0 |
D/D |
5,000 |
950,851 |
|
- |
|
| Robertson Sanford |
Director |
• • – |
2024-04-26 |
4 |
OE |
$22.00 |
$1,518,000 |
D/D |
69,000 |
955,851 |
|
- |
|
| Barry Richard |
Director |
• • – |
2024-04-23 |
4 |
OE |
$22.00 |
$3,873,870 |
I/I |
176,085 |
469,562 |
|
- |
|
| Kupiec James William |
Chief Medical Officer |
• • – |
2024-04-18 |
4 |
OE |
$22.00 |
$33,000 |
D/D |
1,500 |
4,000 |
|
- |
|
| Schoen Eric |
Chief Financial Officer |
• • – |
2024-04-17 |
4 |
OE |
$22.00 |
$33,000 |
D/D |
1,500 |
21,300 |
|
- |
|
| Robertson Sanford |
Director |
– • – |
2023-08-23 |
4 |
B |
$17.45 |
$523,500 |
D/D |
30,000 |
886,851 |
2.39 |
29% |
|
| Barry Richard |
Director |
– • – |
2023-08-22 |
4 |
B |
$16.65 |
$275,907 |
I/I |
16,571 |
293,477 |
2.1 |
31% |
|
| Barry Richard |
Director |
– • – |
2023-08-21 |
4 |
B |
$16.80 |
$32,021 |
I/I |
1,906 |
276,906 |
2.1 |
36% |
|
| Scannon Patrick J Md Phd |
Director |
– • – |
2023-06-12 |
4 |
OE |
$0.95 |
$950 |
D/D |
1,000 |
1,000 |
|
- |
|
| Barbier Remi |
President and CEO |
• • – |
2023-05-24 |
4 |
D |
$25.25 |
$1,205,006 |
D/D |
(47,723) |
734,279 |
|
- |
|
| Barbier Remi |
President and CEO |
• • – |
2023-05-24 |
4 |
OE |
$16.87 |
$1,204,990 |
D/D |
71,428 |
782,002 |
|
- |
|
| Barbier Remi |
President and CEO |
• • – |
2023-05-24 |
4 |
D |
$25.25 |
$241,011 |
I/I |
(9,545) |
380,852 |
|
- |
|
| Barbier Remi |
President and CEO |
• • – |
2023-05-24 |
4 |
OE |
$16.87 |
$240,988 |
I/I |
14,285 |
390,397 |
|
- |
|
| Robertson Sanford |
Director |
– • – |
2023-05-10 |
4 |
OE |
$16.66 |
$165,170 |
D/D |
9,284 |
856,851 |
|
- |
|
| Gussin Robert Z |
Director |
– • – |
2023-05-01 |
4 |
A |
$23.34 |
$165,177 |
D/D |
7,077 |
10,617 |
|
- |
|
83 Records found
|
|
Page 1 of 4 |
|
|
0.12 (4.36%) 
